Antibody Developer Biocytogen Closes Series D+ at CNY 790 Mn
Biocytogen, Beijing-based genetic biotechnology, announced the close of Series D+ fundraising at CNY 790 million. CMB International led the investment, joined by SDIC Venture Capital, China Life Investment Holding Company, 3E Bioventures, Cowin Capital and PICC Capital Equity. The bankroll will help accelerate its animal-based antibody discovery.
The company owns a highly-efficient genetic editing technology platform and provides four anchor services: gene editing, animal & cell models, preclinical services and antibody discovery.